Literature DB >> 19657487

Long-lasting remission induced by rituximab in two cases of refractory autoimmune haemolytic anaemia due to cold agglutinins.

Massimiliano Palombi, Pasquale Niscola, Malgorzata Monika Trawinska, Laura Scaramucci, Marco Giovannini, Alessio Perrotti, Paolo de Fabritiis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19657487      PMCID： PMC2719275          DOI： 10.2450/2008.0066-08

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  5 in total

1.  Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients.

Authors:  Claudia Schöllkopf; Lars Kjeldsen; Ole Weiss Bjerrum; Hans Torben Mourits-Andersen; Johan Lanng Nielsen; Bjarne Egelund Christensen; Bjarne Anker Jensen; Bjarne Bach Pedersen; Ellen Birkerod Taaning; Tobias Wirenfeldt Klausen; Henrik Birgens
Journal:  Leuk Lymphoma       Date:  2006-02

2.  Cost-effectiveness of rituximab in refractory cold agglutinin disease.

Authors:  U Panwar; C Mathews; J O Cullis
Journal:  Int J Lab Hematol       Date:  2008-08       Impact factor: 2.877

3.  Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients.

Authors:  Sigbjørn Berentsen; Elling Ulvestad; Bjørn Tore Gjertsen; Henrik Hjorth-Hansen; Ruth Langholm; Håvar Knutsen; Waleed Ghanima; Fuad Victor Shammas; Geir E Tjønnfjord
Journal:  Blood       Date:  2003-12-30       Impact factor: 22.113

4.  Beneficial effects of rituximab on primary cold agglutinin disease refractory to conventional therapy.

Authors:  Akinori Mori; Jun-Ichi Tamaru; Hajime Sumi; Haruki Kondo
Journal:  Eur J Haematol       Date:  2002-04       Impact factor: 2.997

Review 5.  Cold antibody autoimmune hemolytic anemias.

Authors:  Lawrence D Petz
Journal:  Blood Rev       Date:  2007-09-27       Impact factor: 8.250
  5 in total
  4 in total

1.  Long lasting remission by rituximab in a patient with primary cold agglutinin autoimmune haemolytic anaemia.

Authors:  Marjana Glaser; Andrej Glaser; Marjan Skalicky
Journal:  Wien Klin Wochenschr       Date:  2011-09-28       Impact factor: 1.704

2.  Occurrence of lymphoplasmacytic lymphoma 6 years after amelioration of primary cold agglutinin disease by rituximab therapy.

Authors:  Hiroaki Tanaka; Shinichiro Hashimoto; Yasumasa Sugita; Shio Sakai; Yusuke Takeda; Daijiro Abe; Toshiyuki Takagi; Chiaki Nakaseko
Journal:  Int J Hematol       Date:  2012-08-11       Impact factor: 2.490

Review 3.  Rituximab in the treatment of autoimmune haemolytic anaemia.

Authors:  Chaturaka Rodrigo; Senaka Rajapakse; Lallindra Gooneratne
Journal:  Br J Clin Pharmacol       Date:  2015-05       Impact factor: 4.335

4.  Cold autoimmune hemolytic anemia resolved by rituximab.

Authors:  Massimiliano Palombi; Pasquale Niscola; Alessio Pio Perrotti; Paolo de Fabritiis
Journal:  Asian J Transfus Sci       Date:  2010-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.